1,1-dimethylethyl-N-[2-[[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]amino]-2-oxoethyl]carbamate | 198471-70-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,1-dimethylethyl-N-[2-[[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]amino]-2-oxoethyl]carbamate
• 英文别名: tert-butyl N-[2-[[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylamino]-2-oxoethyl]carbamate
• CAS: 198471-70-4
• 化学式: C₂₃H₂₅N₃O₆S
• 分子量: 471.534
• InChiKey: VEYXRQCMWBOQAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  136
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1,8-diazobicyclo[4.3.0]undec-7-ene 、 BOC-甘氨酸-N-羟基琥柏酰亚胺酯 、 伐地考昔 生成 1,1-dimethylethyl-N-[2-[[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]amino]-2-oxoethyl]carbamate
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS<br/>[FR] DERIVES BENZENESULFONAMIDE SUBSTITUE UTILISABLES COMME PRECURSEURS DES INHIBITEURS DU COX-2
  申请人：G.D. SEARLE & CO.

  公开号：WO1997038986A1

  公开（公告）日：1997-10-23

  (EN) Prodrugs of COX-2 inhibitors of formula (I) are described as being useful in treating inflammation and inflammation-related disorders wherein A is a ring substituent selected from partially unsaturated heterocyclyl, heteroaryl, cycloalkenyl and aryl, wherein A is optionally substituted at a substitutable position with one or more radicals selected from alkylcarbonyl, formyl, halo, alkyl, haloalkyl, oxo, cyano, nitro, carboxyl, alkoxy, aminocarbonyl, alkoxycarbonyl, carboxyalkyl, cyanoalkyl, hydroxyalkyl, haloalkylsulfonyloxy, alkoxyalkyloxyalkyl, carboxyalkoxyalkyl, cycloalkylalkyl, alkenyl, alkynyl, heterocyclyloxy, alkylthio, cycloalkyl, aryl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, and N-alkyl-N-arylaminosulfonyl; wherein R1 is selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio; wherein R2 is selected from hydrido and alkoxycarbonylalkyl; and wherein R3 is selected from alkyl, carboxyalkyl, acyl, alkoxycarbonyl, heteroarylcarbonyl, alkoxycarbonylalkylcarbonyl, alkoxycarbonylcarbonyl, amino acid residue, and alkylcarbonylaminoalkylcarbonyl; provided A is not tetrazolium, or pyridinum; and further provided A is not indanone when R3 is alkyl or carboxyalkyl; or a pharmaceutically-acceptable salt thereof.(FR) La présente invention concerne des précurseurs, inhibiteurs du COX-2, représentés par la formule générale (I) et convenant en thérapie des inflammations et des troubles liés aux inflammations ou l'un de leurs sels galéniques. Dans cette formule générale (I), 'A' est un substituant cyclique appartenant au groupe des hétérocyclyle, hétéroaryle, cycloalkényle et aryle, la substitution de 'A' se faisant éventuellement en une position admettant la substitution, et ce, au moyen d'un ou plusieurs radicaux appartenant au groupe des alkylcarbonyl, formyl, halo, alkyl, haloalkyl, oxo, cyano, nitro, carboxyl, alcoxy, aminocarbonyl, alcoxycarbonyl, carboxyalkyl, cyanoalkyl, hydroxyalkyl, haloalkylsulfonyloxy, alcoxyalkyloxyalkyl, carboxyalcoxyalkyl, cycloalkylalkyl, alkényl, alkynyl, hétérocyclyloxy, alkylthio, cycloalkyl, aryl, hétérocyclyl, cycloalkényl, aralkyl, hétérocyclyalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, aralkényl, alcoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralcoxyalkyl, alcoxycarbonylalkyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralcoxy, arylthio, aralkylthio, alkylsulfinyl,alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-aralkylaminosulfonyl, arylsulfonyl, et N-alkyl-N-arylaminosulfonyl; R1 appartient au groupe des hétérocyclyle, cycloalkyle, cycloalkényle et aryle, R1 étant éventuellement substitué, en une position admettant la substitution, au moyen d'un ou plusieurs radicaux appartenant au groupe des alkyl, haloalkyl, cyano, carboxyl, alcoxycarbonyl, hydroxyl, hydroxyalkyl, haloalcoxyn amino, alkylamino, arylamino, nitro, alcoxyalkyl, alkylsulfinyl, halo, alcoxy et alkylthio; R2 appartient au groupe des hydrido et alcoxycarbonylalkyl; et R3 appartient au groupe des alkyl, carboxyalkyl, acyl, alcoxycarbonyl, hétéroarylcarbonyl, alcoxycarbonylalkylcarbonyl, alcoxycarbonylcarbonyl, radical d'acide aminé et alkylcarbonylaminoalkylcarbonyl; 'A' ne devant être ni tétrazolium ni pyridinium; en outre 'A' ne peut être indanone lorsque R3 est alkyl ou carboxyalkyl.

  描述了公式（I）的COX-2抑制剂的前药在治疗炎症和与炎症相关的疾病中有用，其中A是从部分不饱和杂环基，杂环芳基，环烷基和芳基中选择的环取代基，其中A在可取代位置上可用一个或多个基团进行取代，所述基团从烷基羰基，甲酰基，卤素，烷基，卤素烷基，氧代，氰基，硝基，羧基，烷氧基，氨基羰基，烷氧羰基，羧基烷基，氰基烷基，羟基烷基，卤素烷磺酰氧基，烷氧烷氧基烷基，羧酸烷氧基烷基，环烷基烷基，烯烃基，炔基，杂环氧基，烷硫基，环烷基，芳基，杂环基，环烷基烯烃基，芳基烷基，烷硫基烷基，芳基羰基，芳基烷羰基，芳基烯基，烷氧基烷基，芳硫基烷基，芳氧基烷基，芳烷硫基烷基，芳氧基烷基，烷氧羰基烷基，氨基羰基烷基，烷基氨基羰基，N-芳基氨基羰基，N-烷基-N-芳基氨基羰基，烷基氨基羰基烷基，烷基氨基，N-芳基氨基，N-芳基烷基氨基，N-烷基-N-芳基氨基，N-烷基-N-芳基氨基，氨基烷基，烷基氨基烷基，N-芳基氨基烷基，N-芳基烷基氨基烷基，N-烷基-N-芳基氨基烷基，N-烷基-N-芳基氨基烷基，芳氧基，芳基氧基，芳硫基，芳烷硫基，烷基亚磺酰基，烷基磺酰基，氨基磺酰基，烷基氨基磺酰基，N-芳基氨基磺酰基，芳基磺酰基和N-烷基-N-芳基氨基磺酰基中选择；其中R1选择自杂环基，环烷基，环烷基烯烃基和芳基，其中R1在可取代位置上可用一个或多个基团进行取代，所述基团从烷基，卤素烷基，氰基，羧基烷氧基，羟基，羟基烷基，卤素烷氧基，氨基，烷基氨基，芳基氨基，硝基，烷氧基烷基，烷硫基，卤素，烷氧基和烷硫基中选择；其中R2选择自氢和烷氧羰基烷基；其中R3选择自烷基，羧基烷基，酰基，烷氧羰基，杂环芳基羰基，烷氧羰基烷基羰基，烷氧羰基羰基，氨基酸残基和烷基羰基氨基烷基羰基；前提是A不是四唑或吡啶，且当R3为烷基或羧基烷基时，A不是吲哚酮；或其药学上可接受的盐。
• Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors
  申请人：Pharmacia Corporation

  公开号：US20030069287A1

  公开（公告）日：2003-04-10

  Prodrugs of COX-2 inhibitors and methods of their preparation are described. The prodrugs of COX-2 inhibitors are described as being useful in treating inflammation and inflammation-related disorders.

  本文描述了COX-2抑制剂的前药及其制备方法。所述COX-2抑制剂的前药被描述为在治疗炎症和与炎症相关的疾病方面有用。
• Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors
  申请人：Talley J. John

  公开号：US20050032851A1

  公开（公告）日：2005-02-10

  Prodrugs of COX-2 inhibitors are described as being useful in treating inflammation and inflammation-related disorders.

  COX-2抑制剂的前药被描述为在治疗炎症和炎症相关疾病方面有用。
• Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
  申请人：G.D. Searle LLC

  公开号：EP1288206B1

  公开（公告）日：2008-09-17
• SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS
  申请人：G.D. SEARLE & CO.

  公开号：EP0892791A1

  公开（公告）日：1999-01-27